Sivia Capital Partners LLC Makes New Investment in GSK plc (NYSE:GSK)

Sivia Capital Partners LLC bought a new position in shares of GSK plc (NYSE:GSK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,103 shares of the pharmaceutical company’s stock, valued at approximately $209,000.

Other institutional investors have also modified their holdings of the company. Cohen Investment Advisors LLC acquired a new position in shares of GSK in the second quarter valued at approximately $349,000. Blair William & Co. IL raised its holdings in shares of GSK by 14.9% in the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock worth $1,007,000 after acquiring an additional 3,044 shares during the last quarter. SG Americas Securities LLC lifted its holdings in GSK by 448.7% in the 1st quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock valued at $758,000 after purchasing an additional 14,466 shares in the last quarter. Royal Fund Management LLC grew its stake in GSK by 87.0% in the 3rd quarter. Royal Fund Management LLC now owns 42,456 shares of the pharmaceutical company’s stock worth $1,737,000 after acquiring an additional 19,758 shares during the period. Finally, CreativeOne Wealth LLC acquired a new position in shares of GSK during the 1st quarter valued at about $235,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.8 %

GSK stock opened at $39.13 on Tuesday. The stock has a market capitalization of $81.10 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a 50-day moving average of $41.49 and a two-hundred day moving average of $41.34. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were given a dividend of $0.3843 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.93%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 55.80%.

Analyst Ratings Changes

Several equities research analysts have issued reports on GSK shares. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group boosted their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Buy” and a consensus target price of $50.00.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.00% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.